GR1006492B - Cooperating induction of the apoptosis of prostatic tissue-prevention of prostate cancer - new treatment of peripheral androgenic blocking production of complex tablet. - Google Patents

Cooperating induction of the apoptosis of prostatic tissue-prevention of prostate cancer - new treatment of peripheral androgenic blocking production of complex tablet.

Info

Publication number
GR1006492B
GR1006492B GR20080100368A GR20080100368A GR1006492B GR 1006492 B GR1006492 B GR 1006492B GR 20080100368 A GR20080100368 A GR 20080100368A GR 20080100368 A GR20080100368 A GR 20080100368A GR 1006492 B GR1006492 B GR 1006492B
Authority
GR
Greece
Prior art keywords
prostatic tissue
apoptosis
elimination
prevention
prostate cancer
Prior art date
Application number
GR20080100368A
Other languages
Greek (el)
Inventor
Νικολαος Χρηστου Δημοφιλος
Original Assignee
Νικολαος Χρηστου Δημοφιλος
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Νικολαος Χρηστου Δημοφιλος filed Critical Νικολαος Χρηστου Δημοφιλος
Priority to GR20080100368A priority Critical patent/GR1006492B/en
Priority to PCT/GR2009/000031 priority patent/WO2009144514A2/en
Publication of GR1006492B publication Critical patent/GR1006492B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The induction of apoptosis, by terazosine hydrochloride acting on the elimination plateau of the prostatic tissue due to previous atrophy-degeneration by dutasteride or finasteride, allows the quicker, in short-term and long-term treatment, reduction of the prostatic tissue, in relation to dutasteride or finasteride. The prostate cancer is prevented in practice by the critical elimination of the time margin for the malignant growth or of the progress of an already existing, but undiagnosed one,which has not reached the limit of 110 cells [or the time limit of 8-10 years]. Furthermore, dysplastic-metaplastic cells are early eliminated, due to the activation of the production and subsequent destruction by P53, the apoptotic protein which selectively destroys any morphologically/functionally abnormal cell. With fenretinide, a drastic cooperative prophylaxis is provided, which is harmless for the prevention of cancer in the particular population groups mentioned in the description. The additional use of verapamil/diltiazem in this application field optimize the MDR elimination, the trapping of PgP170, and in practice save the patients to be treated.
GR20080100368A 2008-05-29 2008-05-29 Cooperating induction of the apoptosis of prostatic tissue-prevention of prostate cancer - new treatment of peripheral androgenic blocking production of complex tablet. GR1006492B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GR20080100368A GR1006492B (en) 2008-05-29 2008-05-29 Cooperating induction of the apoptosis of prostatic tissue-prevention of prostate cancer - new treatment of peripheral androgenic blocking production of complex tablet.
PCT/GR2009/000031 WO2009144514A2 (en) 2008-05-29 2009-05-22 Cooperative induction of apoptosis of prostate tissue - prostate cancer prevention - new practice of peripheral androgenic exclusion construction of complex tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20080100368A GR1006492B (en) 2008-05-29 2008-05-29 Cooperating induction of the apoptosis of prostatic tissue-prevention of prostate cancer - new treatment of peripheral androgenic blocking production of complex tablet.

Publications (1)

Publication Number Publication Date
GR1006492B true GR1006492B (en) 2009-07-22

Family

ID=40888074

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20080100368A GR1006492B (en) 2008-05-29 2008-05-29 Cooperating induction of the apoptosis of prostatic tissue-prevention of prostate cancer - new treatment of peripheral androgenic blocking production of complex tablet.

Country Status (2)

Country Link
GR (1) GR1006492B (en)
WO (1) WO2009144514A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113122494B (en) * 2021-04-25 2023-01-31 上海交通大学医学院附属第九人民医院 Construction method of human prostate epithelial cell finasteride drug-resistant model

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker

Also Published As

Publication number Publication date
WO2009144514A2 (en) 2009-12-03
WO2009144514A3 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
PL1871433T3 (en) Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
MX2021000609A (en) Methods of treatment with cyp3a4 substrate drugs.
TW200616615A (en) Compounds and methods for the treatment of cancer
EP1961418A4 (en) The use of isothiocyanates compounds in treating prostatic diseases and skin cancer
BRPI0507039A (en) composition, methods of treating a cancer patient, and inhibiting angiogenesis in a tumor, and
ES2422605T3 (en) Antibody against klotho-beta for use in the treatment of tumors, cancer or cell proliferative disorders
DE602005019010D1 (en) Use of an extract of Angelica sinensis as a growth inhibitor of cancer cells in tumor therapy
EA201391286A1 (en) TREATMENT OF SOLID TUMORS
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
MX2020005547A (en) Modulators of complement activity.
Yakymenko et al. Low intensity radiofrequency radiation: a new oxidant for living cells
RU2013121744A (en) CANCER TREATMENT / METASTASIS INHIBITION
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
CR20220353A (en) Compounds and methods for the targeted degradation of androgen receptor
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
WO2007027344A3 (en) Compounds and methods for the treatment of cancer
MX2021008972A (en) Metal chelator combination therapy for the treatment of cancer.
GR1006492B (en) Cooperating induction of the apoptosis of prostatic tissue-prevention of prostate cancer - new treatment of peripheral androgenic blocking production of complex tablet.
MX2009011901A (en) Pharmaceutical composition for preventing and treating cancer and health food containing the same for preventing and treating cancer.
Cunha et al. Melasma and vitiligo: novel and experimental therapies
CL2021001172A1 (en) Use of tivozanib to treat patients with refractory cancer.
WO2007082104A3 (en) Compounds and methods for the treatment of cancer
Park et al. P253: Comparison of responses to picosecond and nanosecond lasers in the treatment of hyperpigmented skin lesions
RU2010137517A (en) METHOD FOR TREATING LOCAL-BREAST BREAST CANCER WITH TUMOR ANTI-SKIN EXPLOSIONS
Sampath et al. Breast cancer treatment using curcumin, the natural herbal biodielectric

Legal Events

Date Code Title Description
PG Patent granted
ML Lapse due to non-payment of fees